Interleukin-6 receptor antagonists improve outcomes for critically ill Covid-19 patients
In short: Researchers conducting a randomized platform trial found that the drugs tocilizumab and sarilumab improved survival and organ support-free days in critically ill Covid-19 patients. The study observed that patients receiving these interleukin-6 receptor antagonists had better outcomes compared to those receiving standard care.
The study used an adaptive platform trial design to evaluate the efficacy of tocilizumab and sarilumab in patients recently started on organ support in the ICU. Results showed that both drugs met predefined criteria for efficacy, including improved 90-day survival.
Because this was an ongoing adaptive trial, the findings reflect the data collected up to a specific point in time rather than a completed long-term follow-up.
Why it matters: Targeting interleukin-6 receptors may improve survival for patients in intensive care with Covid-19.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Investigators et al. (2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England journal of medicine.
To cite this card, link to https://intellectplus.co.uk/app/health-research-interleukin-6-receptor-antagonists-improve-outcomes-for-crit.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Pandemics & epidemics · More in Health · Latest · A–Z · All topics
